Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 27 articles: HTML format

Single Articles

September 2025
1. OKADA S, Nishikubo M
   Subcutaneous Panniculitis-like T-Cell Lymphoma.
   N Engl J Med. 2025;393:1117.
   PubMed    
   
   
   August 2025
2. ALEMAN A, Van Oekelen O, Melnekoff DT, Grossman L, et al
   Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
   N Engl J Med. 2025;393:823-825.
   PubMed    
   
   
   
3. SVOBODA J, Hexner E, June CH
   Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply.
   N Engl J Med. 2025;393:620.
   PubMed    
   
   
   
4. VAIRAMOORTHY N, Kazi B, Patil V
   Enhanced CAR T-Cell Therapy for Relapsed Lymphoma.
   N Engl J Med. 2025;393:619-620.
   PubMed    
   
   
   May 2025
5. SVOBODA J, Landsburg DJ, Gerson J, Nasta SD, et al
   Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.
   N Engl J Med. 2025;392:1824-1835.
   PubMed     Abstract available
   
   
   
6. PRICA A, Roschewski M, Beale P, Pittaluga S, et al
   Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma.
   N Engl J Med. 2025;392:1760-1762.
   PubMed    
   
   
   February 2025
7. HARRISON SJ, Touzeau C, Kint N, Li K, et al
   CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.
   N Engl J Med. 2025;392:677-685.
   PubMed     Abstract available
   
   
   
8. PERICA K, Jain N, Scordo M, Patel R, et al
   CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53.
   N Engl J Med. 2025;392:577-583.
   PubMed     Abstract available
   
   
   January 2025
9. HERRERA AF, LeBlanc M, Friedberg JW
   Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. Reply.
   N Engl J Med. 2025;392:102.
   PubMed    
   
   
   
10. SHIBUSAWA M, Tanimoto T
    Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
    N Engl J Med. 2025;392:101.
    PubMed    
    
    
    October 2024
11. ARMITAGE JO, Longo DL
    Therapy for Hodgkin's Lymphoma - Can It Get Any Better?
    N Engl J Med. 2024;391:1452-1454.
    PubMed    
    
    
    
12. HERRERA AF, LeBlanc M, Castellino SM, Li H, et al
    Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
    N Engl J Med. 2024;391:1379-1389.
    PubMed     Abstract available
    
    
    
13. KOBBE G, Bruggemann M, Baermann BN, Wiegand L, et al
    Aggressive Lymphoma after CD19 CAR T-Cell Therapy.
    N Engl J Med. 2024;391:1217-1226.
    PubMed     Abstract available
    
    
    September 2024
14. HAMILTON MP, Miklos DB, Alizadeh AA
    Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply.
    N Engl J Med. 2024;391:870-871.
    PubMed    
    
    
    
15. GODFREY J, Querfeld C, Song J
    Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
    N Engl J Med. 2024;391:869-870.
    PubMed    
    
    
    August 2024
16. DORES GM, Morton LM
    T-Cell Neoplasms after B-Cell Neoplasms - The Pre-CAR T-Cell Era.
    N Engl J Med. 2024;391:662-664.
    PubMed    
    
    
    June 2024
17. GOLDSTEIN JS, Alizadeh AA
    ViPOR's Venom - Rationally Targeting DLBCL with Precision.
    N Engl J Med. 2024;390:2209-2211.
    PubMed    
    
    
    
18. MELANI C, Lakhotia R, Pittaluga S, Phelan JD, et al
    Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2024;390:2143-2155.
    PubMed     Abstract available
    
    
    
19. VELEANU L, Lamant L, Sibon D
    Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.
    N Engl J Med. 2024;390:2129-2130.
    PubMed    
    
    
    
20. OZDEMIRLI M, Loughney TM, Deniz E, Chahine JJ, et al
    Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.
    N Engl J Med. 2024;390:2074-2082.
    PubMed     Abstract available
    
    
    
21. HAMILTON MP, Sugio T, Noordenbos T, Shi S, et al
    Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
    N Engl J Med. 2024;390:2047-2060.
    PubMed     Abstract available
    
    
    May 2024
22. CHEN ST, Cochran RL, Jain S, Stagner AM, et al
    Case 15-2024: A 73-Year-Old Woman with Worsening Rash.
    N Engl J Med. 2024;390:1803-1813.
    PubMed    
    
    
    April 2024
23. HU Y, Zhang M, Yang T, Mo Z, et al
    Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
    N Engl J Med. 2024;390:1467-1480.
    PubMed     Abstract available
    
    
    March 2024
24. VIPLER B
    "What's Lymphoma?" - Risks Posed by Immediate Release of Test Results to Patients.
    N Engl J Med. 2024;390:1064-1066.
    PubMed    
    
    
    December 2023
25. CHENG JW, Li JH
    Intravascular Large B-Cell Lymphoma.
    N Engl J Med. 2023;389:2188.
    PubMed    
    
    
    September 2023
26. WESTIN JR, To C, Locke FL
    Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply.
    N Engl J Med. 2023;389:1152-1153.
    PubMed    
    
    
    
27. ZHAO WL, Wu DP, Hu Y
    Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
    N Engl J Med. 2023;389:1152-1153.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.